Search LEXX
Lexaria Bioscience Corp.
Nasdaq · CIK 1348362
Last close2.88
Daily change-0.21 (-6.80%)
10 Years gain-95.71%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
LEXX · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 0831
Fundamental
50.5Momentum
n/aAcceleration
n/aConfidence
77.0Annual Revenue12
Quarterly Revenue40
Annual CFO16
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth17.3 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet13.2 / 15
Shareholder Economics5.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Negative FCF · HIGHLatest free cash flow is negative.
Heavy share dilution · HIGHDiluted share count increased 41.6517%.
High SBC · MEDIUMStock based compensation is high relative to revenue or FCF.
Key Metrics
Revenue Growth TTM-63.11%OK
Revenue CAGR 3Y40.34%OK
Gross Margin100%OK
Operating Margin-4,520.49%OK
FCF Margin-4,333.9%OK
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-169.66%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFO0.44xOK
Diluted Share Growth 1Y41.65%OK
SBC / Revenue367.46%OK
SBC / FCF-8.48%OK
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Aug 31, 2025 | $705,923.00 | $703,203.00 | -$11.88M | -$10.45M | -$10.48M | 99.61% | -1,683.01% | -1,483.88% | -709.38% | 18M |
| 2025 FY Aug 31, 2024 | n/a | $459,456.00 | -$5.75M | -$4.96M | -$5.00M | n/a | n/a | n/a | n/a | 12.38M |
| 2024 FY Aug 31, 2024 | $464,278.00 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| 2024 FY Aug 31, 2023 | $226,208.00 | $194,708.00 | -$6.53M | -$5.88M | -$5.91M | 86.07% | -2,888.5% | -2,614.84% | -307.74% | 6.61M |
| 2023 FY Aug 31, 2022 | $255,397.00 | $183,556.00 | -$6.62M | -$4.88M | -$4.93M | 71.87% | -2,591.67% | -1,929.75% | -316.69% | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $194,000.00 | sum latest 4 fiscal quarters Revenue | OK | 0001640334-26-001166, 0001640334-26-000080 |
| Revenue Growth TTM | -63.11% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001640334-26-001166, 0001640334-26-000080 |
| Revenue CAGR 3Y | 40.34% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001640334-25-002225 |
| Revenue CAGR 5Y | 12.92% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001640334-25-002225 |
| Gross Profit CAGR 3Y | 56.47% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001640334-25-002225 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001640334-26-001166, 0001640334-26-000080 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | 0001640334-26-001166, 0001640334-26-000687 |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001640334-26-001166, 0001640334-26-000080 |
| Operating Margin | -4,520.49% | Operating Income / Revenue | OK | 0001640334-26-001166, 0001640334-26-000080 |
| FCF Margin | -4,333.9% | (CFO - CapEx) / Revenue | OK | 0001640334-26-001166, 0001640334-26-000687 |
| ROIC | -169.66% | NOPAT / Average Invested Capital | OK | 0001640334-26-001166, 0001640334-26-000080 |
| Net Debt / CFO | 0.44x | Net Debt / CFO | OK | 0001640334-26-001166, 0001640334-26-000687 |
| Current Ratio | 10.6x | Current Assets / Current Liabilities | OK | derived |
| SBC / Revenue | 367.46% | SBC / Revenue | OK | 0001640334-26-001166, 0001640334-26-000687 |